Fig. 4.

EMG outcomes assessed in Patient 3 up to 12 months after systemic–intraosseous DT-DEC01 administration. EMG assessment of average MUP duration revealed: A significant increase in the deltoideus by 59.9 ± 7.6%, B increase in the biceps brachii by 31.6 ± 5.5%, C increase in the rectus femoris by 11.3 ± 4.4% and D increase in the gastrocnemius by 11.1 ± 5.5% compared to baseline. The data are expressed as mean ± SEM, and the average of 10 MUP measurements is shown. The statistical significance was assessed by Kruskal–Wallis test, with *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 denoting significant differences. V0a screening visit, V5 3 months, V6 6 months, V7 12 months of visit after DT-DEC01 administration